CLRB · Cellectar Biosciences, Inc. · Earnings Call Transcripts & Audio
$2.34
-0.07 (-2.90%)
At close · Sep 9
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These uncertainties raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements have been prepared on the basis that the Company will continue to operate as a going concern, which contemplates it will be able to realize assets and settle liabilities and commitments in the normal course of business for the foreseeable future. Accordingly, the accompanying consolidated financial statements do not include any adjustments that may result from the outcome of these uncertainties.”View the 10-Q filed Aug 13, 2026
Market Cap
$22.78M
Shares
9.45M
Cellectar Biosciences, Inc. Earnings Call Transcripts
Quarterly earnings calls for Cellectar Biosciences, Inc. (CLRB), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Earnings call
FY26 · Q2
2026-08-13
Cellectar Biosciences, Inc. (CLRB) Q2 2026 Earnings Call Transcript
Confident tone
PDC platform and pipeline expansion
Financing and balance sheet
Regulatory path and accelerated approval
Diluted EPS
$-0.57
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-14
Cellectar Biosciences, Inc. (CLRB) Q1 2026 Earnings Call Transcript
Confident tone
Waldenstrom Macroglobulinemia unmet need
Phase III confirmatory trial design
Iopofosine I-131 CLOVER WaM Phase IIb data
Diluted EPS
$-1.33
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-04
Cellectar Biosciences, Inc. (CLRB) Q4 2025 Earnings Call Transcript
Confident tone
Regulatory progress in EU and US
Iapophysine I-131 / WM lead asset
Data readouts and upcoming medical presentations
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-13
Cellectar Biosciences, Inc. (CLRB) Q3 2025 Earnings Call Transcript
Confident tone
Regulatory progress for iopofosine I-131
Next-generation pipeline (CLR125, CLR225)
PFS data and disclosure timing
Diluted EPS
$-1.41
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-14
Cellectar Biosciences, Inc. (CLRB) Q2 2025 Earnings Call Transcript
Confident tone
Regulatory pathway for Iopofosine I-131 in WM
Next-generation pipeline
European regulatory strategy
Diluted EPS
$-3.39
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Cellectar Biosciences, Inc. (CLRB) Q1 2025 Earnings Call Transcript
Positive tone
FDA and EMA regulatory pathway
Phase 3 study design and comparator
Iopofosine I 131 for Waldenstrom's Macroglobulinemia
Diluted EPS
$-4.30
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-13
Cellectar Biosciences, Inc. (CLRB) Q4 2024 Earnings Call Transcript
Balanced tone
iopofosine / iapopacine clinical data and CLOVER-WaM
Regulatory pathway and NDA delay
Phase 3 study design and timeline
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-18
Cellectar Biosciences, Inc. (CLRB) Q3 2024 Earnings Call Transcript
Confident tone
Confirmatory study requirements
NDA submission and regulatory timeline
CLOVER WaM pivotal study data
Diluted EPS
$-12.13
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-07-23
Cellectar Biosciences, Inc. (CLRB) Q2 2024 Earnings Call Transcript
Positive tone
CLOVER WaM pivotal study data
NDA filing and FDA review
Manufacturing and CMC
Diluted EPS
$-5.43
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
Cellectar Biosciences, Inc. (CLRB) Q1 2024 Earnings Call Transcript
Confident tone
WM pivotal study and NDA submission
Commercial launch preparation and pricing
Manufacturing and supply chain readiness
Diluted EPS
$-27.30
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-27
Cellectar Biosciences, Inc. (CLRB) Q4 2023 Earnings Call Transcript
Confident tone
CLOVER-WaM pivotal trial results
NDA filing and regulatory pathway
European expansion strategy
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Cellectar Biosciences, Inc. (CLRB) Q3 2023 Earnings Call Transcript
Diluted EPS
$-46.50
Audio
Transcript
Slides
8-K10-Q
Showing 1–12 of 12 earnings calls
Key facts
CIK
1279704
CUSIP
15117F880
13F (30d)
23 filings
23 filers
Visit website
Investor relations